跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-BOSENTAN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-BOSENTAN
Authorized
STANDARD
NAT-BOSENTAN
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
31f8e4f2e0dcd348
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
31f8e4f2e0dcd348
Drug Approval Canada Name
NAT-BOSENTAN
Product Name
NAT-BOSENTAN
Status
Marketed
Status Date
2020-04-30
Original Market Date
2020-04-30
Din
02467992
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
48:48.12
Atc Original
C02KX01 BOSENTAN
Atc Name
c 02 kx 01
Aig Number
0145922002
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
BOSENTAN (BOSENTAN MONOHYDRATE)
125 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
31f8e4f2e0dcd348
Type
Standard
Back to Health Canada Approvals